Ociperlimab is a monoclonal antibody commercialized by BeiGene, with a leading Phase III program in Squamous Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 13 clinical trials, of which 4 were completed, 7 are ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Ociperlimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Net Present Value Model: BeiGene Ltd's Ociperlimab

Buy the Model

Premium Insights

The gold standard of business intelligence.

Find out more

The revenue for Ociperlimab is expected to reach an annual total of $179 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Ociperlimab Overview

Ociperlimab (BGB-A1217) is under development for the treatment of solid tumors including advanced hepatocellular carcinoma, end stage small-cell lung cancer,   locally advanced and metastatic non-squamous/squamous non-small cell lung cancer, recurrent or metastatic esophageal squamous cell carcinoma, cervical cancer, recurrent or metastatic HNSCC, gastric/ gastroesophageal adenocarcinoma, relapsed or refractory diffuse large B-cell lymphoma and unspecified indication. The drug candidate is a humanized, IgG1 monoclonal antibody against T cell immunoreceptor with Ig and ITIM domains (TIGIT). It was under development for the treatment of triple negative breast cancer.

BeiGene Overview

BeiGene is a biotechnology company. It specializes in the development and commercialization of immuno-oncology medicines to treat cancers. The company offers BRUKINSA, a BTK (Bruton’s tyrosine kinase) inhibitor against mantle cell lymphoma (MCL). BeiGene also provides Zanubrutinib (BGB-3111), a small molecule inhibitor of BTK to treat B cell malignancies; Tislelizumab (BGB-A317), a monoclonal antibody targeting solid tumors and hematologic cancer; and Pamiparib (BGB-290) against solid tumor malignancies. The company has operations in the US, Australia, Germany, Spain, Switzerland, and Italy. BeiGene is headquartered in the Cayman Islands, the UK.
The company reported revenues of (US Dollars) US$2,458.8 million for the fiscal year ended December 2023 (FY2023), an increase of 73.7% over FY2022. The operating loss of the company was US$1,207.7 million in FY2023, compared to an operating loss of US$1,789.7 million in FY2022. The net loss of the company was US$881.7 million in FY2023, compared to a net loss of US$2,003.8 million in FY2022.

For a complete picture of Ociperlimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 22 April 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.